The endometriosis market is expected to grow steadily over the forecast period (2026–2036), driven by rising disease awareness, improving diagnosis rates, and advancements in noninvasive diagnostic approaches. Furthermore, the introduction of novel therapeutic options such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others is anticipated to address longstanding unmet needs.

LAS VEGAS, March 12, 2026 /PRNewswire/ -- Recently published Endometriosis Market Insights report includes a comprehensive understanding of current treatment practices, endometriosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Endometriosis Market Summary

• The total endometriosis treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest endometriosis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the US reported ~7 million prevalent cases of endometriosis, a number expected to grow by 2036.
• Leading endometriosis companies, such as Bayer, Hope Medicine, Tiumbio, Kissei Pharmaceutical, Gesynta Pharma, Mithra Pharmaceuticals, VaRi Bioscience, and others, are developing new endometriosis treatment drugs that can be available in the endometriosis market in the coming years. 
• The promising endometriosis therapies in clinical trials include HMI-115, Merigolix/TU2670, Linzagolix, Vipoglanstat, Estelle, VR103, and others.

Discover global endometriosis treatment market size and CAGR @ https://www.delveinsight.com/sample-request/endometriosis-market

Key Factors Driving the Growth of the Endometriosis Market 

• Rising Endometriosis Prevalence: The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
• Advancements in Early Diagnostic Techniques for Endometriosis: New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool
• Launch of Emerging Endometriosis Drugs: The dynamics of the endometriosis market are expected to change in the coming years, owing to the launch of emerging therapies such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.

Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the anticipated launch of novel therapies by key players during the forecast period (2026–2036) is expected to positively influence the endometriosis market in the US, driven by the development of safer, disease-modifying treatments with improved pain management.

Endometriosis Market Analysis

• There is no existing cure for endometriosis. Because symptoms can begin as early as a patient's first menstrual period, managing the condition can span decades, including the years when many people hope to become pregnant. 
• Current treatment options include off-label use of oral contraceptives, progestins as the primary medical therapy, and GnRH agonists or antagonists as secondary options. However, GnRH-based treatments induce a low-estrogen state and can cause significant adverse effects such as medication-induced menopause and bone loss. Notably, all of these therapies prevent conception while they are being used.
• In the United States, approved treatments include elagolix (marketed as ORILISSA) for endometriosis-related pain, as well as combination hormone therapies such as relugolix with estradiol and norethindrone acetate (marketed as MYFEMBREE).
• Several new therapies, such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others, are currently in different stages of clinical development.

Endometriosis Competitive Landscape

Some of the endometriosis drugs under development include HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.

Bayer/Hope Medicine's HMI-115 is a novel monoclonal antibody designed to block the prolactin receptor, a central driver of both the formation and maintenance of endometriosis. Prolactin signaling is known to promote lesion growth, inflammation, and pain. By inhibiting this receptor, HMI-115 seeks to reduce endometriosis-related pain and slow lesion development without relying on hormonal suppression.

Tiumbio's TU2670 is an orally administered small-molecule GnRH receptor antagonist that lowers estradiol levels by directly binding to GnRH receptors in the pituitary gland. In contrast to injectable GnRH agonists, which cause deep, menopause-level hormonal suppression and can lead to bone loss and reduced patient comfort, TU2670 allows adjustable, therapeutic-range hormone reduction. This approach aims to maintain effectiveness while minimizing hypoestrogenic side effects and offers greater convenience through oral dosing. A Phase IIa clinical study is currently underway across five European countries to assess TU2670's safety and its ability to relieve endometriosis-associated pain.

Gesynta Pharma is developing vipoglanstat (GS-248), a selective and potent inhibitor of the enzyme mPGES-1. This enzyme plays a crucial role in inflammatory processes and has been specifically linked to endometriosis pathology.

VaRi Bioscience's VR103 vaginal ring provides a continuous release of progestin for three months and is intended to serve as an optimal first-line treatment for endometriosis. Its effectiveness is comparable to that of GnRH agonists and antagonists, but without reducing estrogen levels enough to affect bone mineral density. Its safety and tolerability profile surpasses that of existing progestin-only therapies, with minimal to no estrogen-withdrawal symptoms such as hot flashes, night sweats, vaginal dryness, or mood changes.

The anticipated launch of these emerging therapies are poised to transform the endometriosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the endometriosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about best-selling endometriosis drugs @ Endometriosis Drugs 

Recent Developments in the Endometriosis Market

• In December 2025, Hope Medicine reported that its lead pipeline product, HMI-115, received FTD from the US FDA for the treatment of moderate to severe pain associated with endometriosis.
• In October 2025, Hope Medicine announced the successful completion of a global Phase II trial of HMI-115, a potential first-in-class monoclonal antibody. The company plans to initiate Phase III studies to further assess efficacy and safety in women with moderate to severe endometriosis-associated pain.
• In September 2025, Gesynta Pharma AB announced that its clinical trial application for the company's Phase II trial of vipoglanstat for the treatment of endometriosis had been approved by the UK authorities. The clinical trial, named NOVA, intends to evaluate the efficacy and safety of vipoglanstat against placebo in approximately 190 patients with endometriosis across several European countries.
• In March 2025, TiumBio's partner Hansoh Pharma expanded Merigolix (HS-10518) development to include Assisted Reproductive Technology (ART), broadening its therapeutic scope beyond endometriosis.

What is Endometriosis?

Endometriosis is a chronic condition in which tissue similar to the lining of the uterus begins to grow outside the uterus, often on the ovaries, fallopian tubes, or other pelvic organs. These abnormal growths respond to hormonal changes during the menstrual cycle, causing inflammation, scarring, and sometimes the formation of cysts. Because this tissue cannot exit the body during menstruation, it can lead to severe pelvic pain, heavy periods, pain during intercourse, and sometimes fertility challenges. Although endometriosis is long-term, its symptoms can be managed through medical treatments, lifestyle adjustments, and, in some cases, surgery.

Endometriosis Epidemiology Segmentation

The endometriosis epidemiology section provides insights into the historical and current endometriosis patient pool and forecasted trends for the leading markets. In the US, diagnosed prevalent cases of endometriosis are predominantly managed by gynecologists, accounting for about 3 million cases in 2025 and generalists represent the second-largest prescriber group, managing roughly 500,000 cases in 2025.

The endometriosis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Prevalent Cases of Endometriosis
• Diagnosed Prevalent Cases of Endometriosis
• Age-specific Diagnosed Prevalent Cases of Endometriosis
• Stage-specific Diagnosed Prevalent Cases of Endometriosis
• Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis
• Treated Cases of Endometriosis

Scope of the Endometriosis Market Report

• Therapeutic Assessment: Endometriosis current marketed and emerging therapies
• Endometriosis Market Dynamics: Key Market Forecast Assumptions of Emerging Endometriosis Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

Download the report to understand top endometriosis therapies and market trends @ Endometriosis Market Analysis

Table of Contents

Related Reports

Endometriosis Clinical Trial Analysis 

Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Hope Medicine Inc, Gesynta Pharma AB, Changchun GeneScience Pharmaceutical Co., Ltd., TiumBio, Jiangsu Hengrui Medicine Co, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Temple Therapeutics, Cartherics Pty Ltd, among others.

Endometriosis Pain Market

Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies including Horizon Therapeutics (Amgen), Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Servier, Novartis, Johnson & Johnson, among others.

Endometriosis Pain Clinical Trial Analysis 

Endometriosis Pain Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com  

+14699457679

www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/endometriosis-market-expected-to-achieve-significant-cagr-during-the-forecast-period-20262036-driven-by-innovative-treatment-options--delveinsight-302711899.html

Die Galenica-Tochtergesellschaft Bichsel stellt ihre defizitäre pharmazeutische Produktion bis Ende 2026 ein und richtet ihr Geschäft künftig auf Home-Care-Dienstleistungen aus. Nach Abschluss des gesetzlich vorgesehenen Konsultationsverfahrens mit der Mitarbeitendenvertretung bestätigte der Verwaltungsrat, dass ein wirtschaftlich tragfähiger Weiterbetrieb der Produktionssparte nicht möglich sei. Trotz kontinuierlicher Investitionen liessen sich die bestehenden Anlagen und Gebäude laut Unternehmen nicht mehr aufrechterhalten.

Im Zuge der Neuausrichtung reduziert Bichsel seinen Stellenabbau leicht: Statt der ursprünglich angekündigten 170 Stellen sollen nun 152 Arbeitsplätze wegfallen. In den kommenden Wochen wird geprüft, wie viele der betroffenen Mitarbeitenden innerhalb des Galenica-Netzwerks weiterbeschäftigt werden können. Die Mitarbeitenden sollen in den nächsten Tagen individuell über ihre persönliche Situation informiert werden.

Für die von der Schliessung betroffenen Beschäftigten hat das Unternehmen einen ausgebauten Sozialplan aufgelegt. Dieser berücksichtigt Faktoren wie Alter und Dienstjahre und enthält eine Härtefallregelung. Zudem unterstützt Bichsel die Mitarbeitenden bei der beruflichen Neuorientierung. Nach Unternehmensangaben sind die konstruktiven Vorschläge der Mitarbeitendenvertretung in die Ausgestaltung des Sozialplans eingeflossen und haben dessen Gestaltung massgeblich geprägt.

Auf der Kundenseite will Bichsel die Versorgungssicherheit im Übergang gewährleisten. Das Unternehmen plant, die Belieferung mit den wichtigsten Produkten bis Ende 2026 sicherzustellen, während parallel der Fokus auf den Ausbau der Home-Care-Dienstleistungen gelegt wird. Damit reagiert die Galenica-Gruppe auf die anhaltenden wirtschaftlichen Herausforderungen in der Produktion und setzt verstärkt auf Bereiche, in denen sie mittel- bis langfristig grössere Chancen sieht.